Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: Methodological aspects and clinical applications

Diabetes and Metabolism

Volumn 22, Issue 6, 1996, Pages 397-406

  Scheen, A J ^a,b   Castillo, M J ^b,c   Lefebvre P J ^b  

^a CHU SART TILMAN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

glucagon; insulin secretion; secondary diabetes; test; Type 1 diabetes; Type 2 diabetes

Indexed keywords

C PEPTIDE; CLONIDINE; DOXAZOSIN; GLUCAGON; INSULIN; METOPROLOL; SULFONYLUREA DERIVATIVE; VERAPAMIL;

DOSE RESPONSE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW;

ARGININE; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0029823416     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. McCulloch DK, Palmer JP. The appropriate use of β-cell function testing in the preclinical period of type 1 diabetes. Diabetic Med, 1991, 8, 800-804.
2. Porte D Jr. β-cells in type II diabetes mellitus. Diabetes. 1991, 40, 166-180.
3. Leahy JL. Natural history of β-cell dysfunction in NIDDM. Diabetes Care, 1990, 13, 992-1010.
4. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 1992, 15, 318-368.
5. Hovorka R, Jones RH. How to measure insulin secretion. Diabetes Metab Rev, 1994, 10, 91-117.
6. Scheen AJ, Paquot N, Letiexhe MR, Castillo MJ, Lefèbvre PJ. Comment mesurer la sécrétion insulinique en pratique ? Diabete Metab. 1995, 21, 458-464.
7. Samols E, Marri G, Marks V. Promotion of insulin secretion by glucagon. Lancet. 1965, 2, 415-416.
8. Samols E. Glucagon and insulin secretion. In : Lefèbvre PJ, ed. Glucagon I. Springer-Verlag, Berlin Heidelberg New York Tokyo, 1983, 485-518.
9. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual β-cell function in diabetes mellitus. Diabetes, 1977, 26, 605-610.
10. Gjessing HJ, Damsgaard EM, Matzen LE, Froland A, Faber OK. Reproducibility of β-cell function estimates in non-insulin-dependent diabetes mellitus. Diabetes Care, 1987, 10, 558-562.
11. Gottsäter A, Landin-Olsson M, Fernlund P, Gullberg B, Lernmark A. Pancreatic β-cell function evaluated by intravenous glucose and glucagon stimulation. A comparison between insulin and C-peptide to measure insulin secretion. Scand J Clin Lab Invest, 1992, 52, 631-639.
12. Scheen A, Gorus FK, Letiexhe M, et al. A multicenter evaluation of the reprodudbility of early insulin response to glucose. Diab Res Clin Pract, 1996 (in press).
13. Kolendorf K, Thorsteinsson B, Billebolle P, Poulsen S. Correlation between the routine 6-min C-peptide values and AUC after I.V. glucagon injection in NIDDM patients. Horm Metab Res, 1982, 14, 675-676.
14. Castillo MJ, Scheen AJ, Lefèbvre PJ. Modified glucagon test allowing simultaneous estimation of insulin secretion and insulin sensitivity : application to obesity, insulin-dependent diabetes mellitus, and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1995, 80, 393-399.
15. Lefèbvre PJ, Scheen AJ. Routes of glucagon administration. Int Glucagon Monitor, 1994, 4, 1-6.
16. Mühlhauser I, Koch J, Berger M. Pharmacokinetics and bioavailability of injected glucagon : differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care, 1985, 8, 39-42.
17. Scheen AJ. The glucagon test for evaluating insulin secretion. In : Glucagon III (Lefèbvre P.J., ed), Springer Verlag, Berlin, 1996 (in press).
18. Lefèbvre PJ, Luyckx S. Lipolytic action of glucagon in vitro and in vivo. In : Vague J (ed) Physiopathology of adipose tissue. Excerpta Medica, Amsterdam London New York, 1969, pp 257-267.
19. Samols E, Marri G, Marks V. Interrelationship of glucagon, insulin and glucose. The insulinogenic effect of glucagon. Diabetes, 1966, 15, 855-866.
20. Ahren B, Nobin A, Schersten B. Insulin and C-peptide secretory responses to glucagon in man : studies on the dose-response relationships. Acta Med Scand, 1987, 221, 185-190.
21. Snorgaard O, Hasselstrom K, Lumholtz IB, Thorsteinsson B, Siersbaek-Nielsen K. Insulin/C-peptide response to intravenous glucagon. A dose-response study in normal and non-insulin-dependent diabetic subjects. Acta Endocrinol, 1988, 117, 109-115.
22. Sarlund H, Siitonen O, Laakso M, Pyörälä K. Repeatability of C-peptide response in glucagon stimulation test. Acta Endocrinol, 1987, 114, 515-518.
23. Arnold-Larsen S, Madsbad S, Kühl C. Reproducibility of the glucagon test. Diabetic Med 1987, 4, 288-303.
24. Scheen AJ, Paolisso G, Juchmes J, Lefèbvre PJ. Insulin secretion rate after intravenous glucagon injection : kinetics reproducibility and potentiation by increasing initial blood glucose levels (Abstract). Diabetologia, 1989, 32, 538A.
25. Castillo MJ, Scheen AJ, Paolisso G, Lefèbvre PJ. Exhaustion of blood glucose response and enhancement of insulin response after repeated glucagon injections in type 2 diabetes : potentiation by progressive hyperglycemia. Ann Endocrinol, 1996, in press.
26. Ganda OP, Day JL, Soeldner JS, Connon JJ, Gleason RE. Reproducibility and comparative analysis of repeated intravenous and oral glucose tolerance tests. Diabetes, 1978, 27, 715-725.
27. Clarson C, Daneman D, Drash AL, Becker DJ, Ehrlich RM. Residual β-cell function in children with IDDM : reproducibility of testing and factors influencing insulin secretory reserve. Diabetes Care, 1987, 10, 33-38.
28. Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppälä P. C-peptide determination in the choice of treatment in diabetes mellitus. Scand J Clin Lab Invest, 1986, 46, 655-663.
29. Oakley NW, Harrigan P, Kissebah AH, Kissin EA, Adams PW. Factors affecting insulin response to glucagon in man. Metabolism, 1972, 21, 1001-1007.
30. Madsbad S, Sauerbrey N, Moller-Jensen B, Krarup T, Kühl C. Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type 1 (insulin-dependent) diabetic patients. Acta Med Scand, 1987, 222, 71-74.
31. Gjessing HJ, Reinholdt B, Faber OK, Pedersen O. The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus. Acta Endocrinol, 1991, 124, 556-562.
32. Gjessing HJ, Reinholdt B, Pedersen O. The plasma C-peptide and insulin responses to stimulation with intravenous glucagon and a mixed meal in well controlled type 2 (non-insulin-dependent) diabetes mellitus : dependency on acutely established hyperglycaemia. Diabetologia, 1989, 32, 858-863.
33. Rönnemaa T. Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients. Scand J Clin Invest, 1986, 46, 345-349.
34. Nosari I, Lepore G, Maglio ML, Cortinovis F, Pagani G. The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes. J Endocrinol Invest, 1992, 15, 143-146.
35. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance : implications for the management of diabetes. Diabetologia, 1985, 28, 119-121.
36. Gjessing HJ, Reinhold B, Pedersen O. The effect of chronic hyperglycaemia on the islet β-cell responsiveness in newly diagnosed type 2 diabetes. Diabetic Med, 1992, 9, 601-604.
37. Hsieh SD, Iwamoto Y, Matsuda A, Kuzuya T. Pancreatic β-cell secretion after oral glucose and intravenous glucagon : different responses to dietary control of plasma glucose in newly diagnosed patients with NIDD. Metabolism, 1987, 36, 384-387.
38. Wolffenbuttel BH, Menheere PP, Nijst L, Rondas-Colbers GJ, Sels JP. Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus : support for the concept of glucose toxicity. Neth J Med, 1992, 40, 277-282.
39. Miki H, Matsuyama T, Fujii S, Komatsu R, Nishioeda Y, Omae T. Glucagon-glucose (GG) test for the estimation of the insulin reserve in diabetes. Diab Res Clin Pract, 1992, 18, 99-105.
40. Vialettes B, Zevacq-Mattei C, Thirion X et al. Acute insulin response to glucose and glucagon in subjects at risk of developing type 1 diabetes. Diabetes Care, 1993, 16, 973-977.
41. Sarlund H, Laakso M, Pyörälä K, Penttilä. Fasting, postprandial and postprandial plus glucagon-stimulated plasma C-peptide levels in non-insulin-dependent diabetics and in control subjects. Acta Med Scand, 1987, 221, 377-383.
42. Small M, Cohen HN, Beastall GH, MacCuish AC. Comparison of oral glucose loading and intravenous glucagon injection as stimuli to C-peptide secretion in normal men. Diabetic Med, 1985, 2, 181-183.
43. Hoekstra JB, Van Rijn HJM, Thijssen JHT, Erkelens DW. C-peptide reactivity as a measure of insulin dependency in obese diabetic patients treated with insulin. Diabetes Care, 1982, 5, 585-591.
44. Ganda OP, Srikanta S, Brink SJ, et al. Differential sensitivity to beta cell secretagogues in "early" Type 1 diabetes mellitus. Diabetes, 1984, 33, 516-521.
45. Lanng S, Thorsteinsson B, Roder ME et al. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endncrinol, 1993, 128, 207-214.
46. Jayyab AK, Heding LG, Czyzyk A, Malczewski B, Krolewski P. Serum C-peptide and IRI levels after administration of glucagon and glucose in non-insulin-dependenl diabetics. Horm Metab Res, 1982, 14, 112-116.
47. Kanatsuka A, Makino H, Sakurada M, et al. First-phase insulin response to glucose in nonobese or obese subjects with glucose intolerance : analysis by C-peptide secretion rate. Metabolism, 1988, 37, 878-884.
48. Ahren B, Schersten B, Agardh CD, Lundquist I. Immunoreactive insulin and C-peptide responses to various insulin secretory stimuli in subjects with type 2 diabetes and in control subjects during continuous glucose monitoring. Acta Med Scand, 1981, 210, 337-348.
49. Heaton DA, Lazarus NR, Pyke DA, Leslie RDG. Beta-cell response to intravenous glucose and glucagon in non-diabetic twins of patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1989, 32, 814-817.
50. Mirel RD, Ginsberg-Fellner F, Horwitz DL, Rayfield EJ. C-peptide reserve in insulin-dependent diabetics : comparative responses to glucose, glucagon and tolbutamide. Diabetologia, 1980, 19, 183-188.
51. Escobar-Jimenez F, Herrera Pombo JL, Gomez-Villalba R, Nunez del Carril J, Aguilar M, Rovira A. Standard breakfast test : an alternative to glucagon testing for C-peptide reserve ? Horm Metab Res, 1990, 22, 339-341.
52. Gjessing HJ, Damsgaard EM, Matzen LE, Faber OK, Froland A. The β-cell response to glucagon and mixed meal stimulation in non-insulin-dependent diabetes. Scand J Clin Lab Invest, 1988, 48, 771-777.
53. Koskinen PJ, Viikari JSA, Irjala KMA. Glucagon-stimulated and post-prandial plasma C-peptide values as measures of insulin secretory capacity. Diabetes Care, 1988, 11, 318-322.
54. Seino Y, Kurahachi H, Goto Y, Taminato T, Ikeda M, Imura H. Comparative insulinogenic effects of glucose, arginine and glucagon in patients with diabetes mellitus, endocrine disorders and liver diseases. Acta Diabetol Lat, 1975, 12, 89-99.
55. Numata K, Tanaka K, Saito M, Shishido T, Inoue S. Very low calorie diet-induced weight loss reverses exaggerated insulin secretion in response to glucose, arginine and glucagon in obesity. Int J Obesity, 1993, 17, 103-108.
56. Gjessing HJ, Matzen LE, Froland A, Faber OK. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics. Diabetes Care, 1987, 10, 487-490.
57. Gjessing HJ, Matzen LE, Faber OK, Froland A. Fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia, 1989, 32, 305-311.
58. Matsuda A, Kamata I, Iwamoto Y, Sakamoto Y, Kuzuya T. A comparison of serum C-peptide responses to intravenous glucagon and urine C-peptide as indexes of insulin dependence. Diabetes Res Clin Pract, 1985, 1, 161-167.
59. Poulsen S, Billesbolle P, Kollendorf K, Thorsteinsson B. The C-peptide response to glucagon injection in IDDM and NIDDM patients. Horm Metab Res, 1985, 17, 39-40.
60. Vahlkamp T, Lutjens A, Nauta EH. The glucagon-stimulated C-peptide test : an aid in classification of patients with diabetes mellitus. Neth J Med, 1990, 36, 196-199.
61. Scheen AJ, Castillo MJ, Lefèbvre PJ. Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement. Diabete Metab, 1996, 22, 456-459.
62. Hendriksen C, Faber OK, Drejer J, Binder C. Prevalence of residual β-cell function in insulin treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia, 1977, 13, 616-619.
63. Montana E, Fernandez-Castaner M, Rosel P, Gomez J, Soler J. Age, sex and ICA influence on β-cell secretion during the first year after diagnosis of type 1 diabetes mellitus. Diabete Metab, 1991, 17, 460-468.
64. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T. Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care, 1992. 15, 66-74.
65. Vague P, Picq R, Bernal M, Lassmann-Vague V, Vialettes B. Effect of nicotinamide treatment on the residual insulin secretion in Type 1 (insulin-dependent) diabetic patients. Diabetolocia, 1989, 32, 316-321.
66. Skyler JS, Rabinovitch A. Cyclosporine in recent onset type 1 diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group. J Diab Compilc, 1992, 6, 77-88.
67. Dupre J, Jenner MR, Mahon JL, Purdon C, Rodger NW, Stiller CR. Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine. Diabetes, 1991, 40, 598-604.
68. Cottrell DA, Henry ML, O'Dorisio TM, Tesi RJ, Ferguson R,M Osei K. Sequential metabolic studies of pancreas allograft function in type 1 diabetic recipients. Diabetic Med, 1992, 9, 438-443.
69. Osei K, Henry ML, O'Dorisio TM, Tesi RJ, Sommer BG, Ferguson RM. Physiological and pharmacological stimulation of pancreatic islet hormone secretion in type 1 diabetic pancreas allograft recipients. Diabetes, 1990, 39, 1235-1242.
70. Nyberg G, von Schenck H, Norden G, Hedman L, Frisk B. Glucagon-stimulated serum C-peptide levels in the early period following pancreas transplantation. Transplant Proc. 1990, 22, 647-648.
71. Scharp DW, Swanson CJ, Olack BJ et al. Protection of encapsulated human islets implanted without immunosuppression in patients with type-I or type-II diabetes and in non-diabetic control subjects. Diabetes, 1994, 43, 1167-1170.
72. Crockford PM, Hazzard WR, Williams RH. Insulin response to glucagon. The opposing effects of diabetes and obesity. Diabetes, 1969, 18, 216-224.
73. Laakso M, Rönnemaa T, Sarlund H, Pyöräl̈a K, Kallio V. Factors associated with fasting and postglucagon plasma C-peptide levels in middle-aged insulin-treated diabetic patients. Diabetes Care, 1989, 12, 83-88.
74. Madsbad S, Krarup T, McNair P et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand, 1981, 210, 153-156.
75. Gjessing HJ, Matzen LE, Pedersen PC, Faber OK, Froland A. Insulin requirement in non-insulin-dependent diabetes mellitus : Relation to simple tests of islet β-cell function and insulin sensitivity. Diabetic Med, 1988, 5, 328-332.
76. Hother-Nielsen O, Faber O, Schwartz-Sorensen N, Beck-Nielsen H. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care, 1988, 11, 531-537.
77. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis in type II diabetic patients. Diabetes Care, 1993, 16, 902-910.
78. Zavala AV, Fabiano de Bruno LE, Cardoso AI et al. Cellular and humoral autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Diabelologia, 1992, 35, 1159-1164.
79. Niskanen L, Karjalainen J, Siitonen O, Uusitupa M. Metabolic evolution of type 2 diabetes : a 10-year follow-up from the time of diagnosis. J Intern Med, 1994, 236, 263-270.
80. Kyllastinen M, Elfving S. Serum C-peptide concentrations and their value in evaluating the usefulness of insulin therapy in elderly diabetics. Gerontology, 1986, 32, 317-326.
81. Viikari J, Ronnemaa T, Koskinen P. Glucagon C-peptide test as a measure of insulin requirement in type 2 diabetes : evaluation of stopping insulin therapy in eleven patients. Ann Clin Res, 1987, 19, 178-182.
82. Castillo MJ, Scheen AJ, Paolisso G, Lefèbvre PJ. The addition of glipizide to insulin therapy in type II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol, 1987, 116, 364-372.
83. Scheen AJ, Castillo MJ, Lefèbvre PJ. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. Acta Clin Belg, 1993, 48, 259-268.
84. Castillo MJ, Scheen AJ, Lefèbvre PJ. Amylin/Islet amyloid polypeptide. Biochemistry, physiology and pathophysiology. Diabete Metab, 1995, 21, 3-25.
85. Van Jaarsveld BC, Hackeng WHL, Lips CJM, Erkelens DW. Plasma concentrations of islet amyloid polypeptide after glucagon administration in type 2 diabetic patients and non-diabetic subjects. Diabetic Med, 1993, 10, 327-330.
86. Del Prato S, Tiengo A. Diabetes secondary to acquired disease of the pancreas. In : Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes. John Wiley, Chichester. 1992, 197-220.
87. Stastna R, Karasova L, Svacek J et al. Endocrine pancreatic secretion in patients after acute pancreatitis. Pancreas, 1990, 5, 358-360.
88. Cavallini G, Bovo P, Zamboni M et al. Exocrine and endocrine functional reserve in the course of chronic pancreatitis as studied by maximal stimulation tests. Dig Dis Sci, 1992, 37, 93-96.
89. Cavallini G, Vaona B, Bovo P et al. Diabetes in chronic alcoholic pancreatitis. Role of residual beta cell function and insulin resistance. Dig Dis Sci. 1993, 38, 497-501.
90. Simon M, Le Mignon L, Edan G, Le Reun M, Hespel JP. Diabetes « d'autres types » : Pancréatite chronique et hémochromatose. J Diabetol Hôtel Dieu, 1984, Flammarion Médecine-Sciences, 85-114.
91. Braasch JW, Vito L, Nugent FW. Total pancreatectomy for end-stage chronic pancreatitis. Ann Surg, 1978, 188, 317-322.
92. Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. J Pediatrics, 1991, 118, 715-723.
93. Permert J, Ihse I, Jorfeldt L, Von Schnck H, Arqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surgery, 1993, 159, 101-107.
94. Fogar P, Basso D, Panozzo MP et al. C-peptide pattern in patients with pancreatic cancer. Anticancer Res, 1993, 2557-2580.
95. Permert J, Ihse I, Jorfeldt L, Von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surgery, 1993, 80, 1047-1050.
96. Jacobs ML, Verhoog S, Van der Linden WH, Huisman WM, Wallenburg HC, Weber RF. Glucagon stimulation test : assessment of β-cell function in gestational diabetes mellitus. Eur J Obst Gynecol, 1994, 56, 27-30.
97. Kobayashi N, Tamai H, Takii M, Matsubayashi S, Nakagawa T. Pancreatic β-cell functioning after intravenous glucagon administration in anorexia nervosa. Acta Psychiat Scand, 1992, 85, 6-10.
98. O'Byrne S, Feely J. Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part I and part II). Drugs, 1990, 40, 6-18 and 203-219.
99. Ferlito S, Del Campo F, Damante G, Di Vincenzo S, Patané M, Modica L. The effect of metoprolol on blood glucose, insulin and C-peptide response to glucagon in non-insulin dependent diabetics. Acta Ther, 1983, 9, 53-60.
100. Ferlito S, Del Campo F, Damante G, Di Vincenzo S, Indelicato G, Raudino M. Influence of clonidine on blood glucose, insulin and C-peptide response to glucagon in non-insulin-dependent diabetics. IRCS Med Sci, 1983, 11, 349.
101. Röjdmark S, Andersson DEH, Hed R, Sundblad L. Effect of verapamil on glucose response to intravenous injection of glucagon and insulin in healthy subjects. Horm Metab Res, 1980, 12, 285-290.
102. Röjdmark S, Andersson DEH, Hed R, Sundblad L. Calcium-antagonistic effects on glucose response to intravenous injection of glucagon in patients with non insulin-dependent diabetes mellitus and in normoglycemic subjects. Horm Metab Res, 1981, 13, 664-667.
103. Scheen AJ, Castillo M, Salvatore T, Lefèbvre PJ. Lack of deleterious effects of the alpha-1 adrenoceptor blocking agent doxazosin on insulin secretion and insulin sensitivity in healthy men. Cur Ther Res. 1989, 46, 200-209.